Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maxcyte (MXCT) Finished Goods (2020 - 2025)

Maxcyte (MXCT) has disclosed Finished Goods for 6 consecutive years, with $3.3 million as the latest value for Q3 2025.

  • On a quarterly basis, Finished Goods fell 26.05% to $3.3 million in Q3 2025 year-over-year; TTM through Sep 2025 was $3.3 million, a 26.05% decrease, with the full-year FY2024 number at $3.9 million, down 34.3% from a year prior.
  • Finished Goods was $3.3 million for Q3 2025 at Maxcyte, down from $3.5 million in the prior quarter.
  • In the past five years, Finished Goods ranged from a high of $6.0 million in Q1 2024 to a low of $2.3 million in Q2 2021.
  • A 5-year average of $3.9 million and a median of $3.5 million in 2023 define the central range for Finished Goods.
  • Peak YoY movement for Finished Goods: soared 121.46% in 2023, then tumbled 40.19% in 2025.
  • Maxcyte's Finished Goods stood at $2.5 million in 2021, then rose by 16.25% to $2.9 million in 2022, then skyrocketed by 103.99% to $6.0 million in 2023, then tumbled by 34.3% to $3.9 million in 2024, then fell by 14.72% to $3.3 million in 2025.
  • Per Business Quant, the three most recent readings for MXCT's Finished Goods are $3.3 million (Q3 2025), $3.5 million (Q2 2025), and $3.6 million (Q1 2025).